BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19342968)

  • 1. Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.
    Asemissen AM; Haase D; Stevanovic S; Bauer S; Busse A; Thiel E; Rammensee HG; Keilholz U; Scheibenbogen C
    J Immunother; 2009 May; 32(4):370-5. PubMed ID: 19342968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
    Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
    Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of both CD8+ and CD4+ T-cell-mediated responses in colorectal cancer patients by colon antigen-1.
    Maccalli C; Di Cristanziano V; Fodale V; Corsi D; D'Agostino G; Petrangeli V; Laurenti L; Guida S; Mazzocchi A; Arienti F; Perrone MP; Castelli C; Rivoltini L; Zagonel V; Tartaglia M; Parmiani G; Belardelli F
    Clin Cancer Res; 2008 Nov; 14(22):7292-303. PubMed ID: 18974390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of new cytotoxic T-lymphocyte epitopes from cancer testis antigen HCA587.
    Xing Q; Pang XW; Peng JR; Yin YH; Li Y; Yu X; Zhou SP; Zhang Y; Chen WF
    Biochem Biophys Res Commun; 2008 Jul; 372(2):331-5. PubMed ID: 18498761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays.
    Weinzierl AO; Maurer D; Altenberend F; Schneiderhan-Marra N; Klingel K; Schoor O; Wernet D; Joos T; Rammensee HG; Stevanović S
    Cancer Res; 2008 Apr; 68(7):2447-54. PubMed ID: 18381453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
    Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
    Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
    Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
    J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers.
    Unger WW; Velthuis J; Abreu JR; Laban S; Quinten E; Kester MG; Reker-Hadrup S; Bakker AH; Duinkerken G; Mulder A; Franken KL; Hilbrands R; Keymeulen B; Peakman M; Ossendorp F; Drijfhout JW; Schumacher TN; Roep BO
    J Autoimmun; 2011 Nov; 37(3):151-9. PubMed ID: 21636247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes.
    Lim JB; Provenzano M; Kwon OH; Bettinotti M; Caruccio L; Nagorsen D; Stroncek D
    Exp Hematol; 2006 Mar; 34(3):296-307. PubMed ID: 16543064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
    Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
    Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a naturally processed T cell epitope derived from the glioma-associated protein SOX11.
    Schmitz M; Wehner R; Stevanovic S; Kiessling A; Rieger MA; Temme A; Bachmann M; Rieber EP; Weigle B
    Cancer Lett; 2007 Jan; 245(1-2):331-6. PubMed ID: 16504379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wildtype p53-specific antibody and T-cell responses in cancer patients.
    Pedersen AE; Stryhn A; Justesen S; Harndahl M; Rasmussen S; Donskov F; Claesson MH; Pedersen JW; Wandall HH; Svane IM; Buus S
    J Immunother; 2011; 34(9):629-40. PubMed ID: 21989411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.
    Maia S; Haining WN; Ansén S; Xia Z; Armstrong SA; Seth NP; Ghia P; den Boer ML; Pieters R; Sallan SE; Nadler LM; Cardoso AA
    Cancer Res; 2005 Nov; 65(21):10050-8. PubMed ID: 16267031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.